Previous close | 5.14 |
Open | 5.21 |
Bid | 5.13 x 200 |
Ask | 6.57 x 200 |
Day's range | 5.05 - 5.27 |
52-week range | 1.86 - 9.01 |
Volume | |
Avg. volume | 14,801 |
Market cap | 13.61M |
Beta (5Y monthly) | 1.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -236.13 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.00 |
In this piece, we will take a look at the 11 best ASX stocks to buy now. If you want to skip our introduction to the Australian stock market, then you can take a look at the 5 Best ASX Stocks To Buy Now. With a market capitalization of $1.5 trillion, the Australian stock exchange, […]
-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit- -Second Subject Scheduled to Receive BB-301 in February 2024- -23 Subjects Enrolled into the Oculopharyngeal Muscular Dystrophy Natural History Study with Multiple Subjects Eligible for entry into the Phase 1b/2a Clinical Treatment Study in 2024- HAYWARD, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Benite
Announcement marks the initiation of the first clinical trial conducted in human subjects employing Benitec’s “Silence and Replace” DNA-directed RNA interference gene therapy platformHAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, tod